期刊文献+

脐带间充质干细胞源外泌小体减轻糖尿病模型小鼠心肌纤维化 被引量:3

Human umbilical mesenchymal stem cell-derived exosome attenuates cardiac fibrosis in diabetic mice
下载PDF
导出
摘要 目的:探讨脐带间充质干细胞外泌小体对糖尿病模型小鼠心肌纤维化的保护作用。方法:6~8周C57BL/6雄性小鼠随机分为3组:对照组、糖尿病模型组和糖尿病+外泌小体组。采用高脂饮食连续喂养5周后,联合小剂量多次(45 mg/kg,每周1次,连续5周)腹腔注射链脲佐菌素的方法诱导糖尿病(血糖≥16.7 mmol/L)模型。糖尿病+外泌小体组在糖尿病造模后,经尾静脉每周注射1次外泌小体,连续注射4周;对照组和糖尿病组予等体积的生理盐水连续注射4周。利用小动物彩色多普勒超声诊断仪检测小鼠心功能指标;然后取腹主动脉血,用生化比色法检测葡萄糖和游离脂肪酸的含量;同时取心脏组织,HE染色观察心肌纤维的结构变化;Masson染色观察心肌纤维化水平。结果:超声心动图结果显示,与对照组相比,糖尿病组较对照组的左心室舒张末期内径和左心室收缩末期内径增大(分别P<0.05和P<0.01),射血分数和室壁缩短率下降(P<0.01);糖尿病+外泌小体组较糖尿病组的左心室收缩末期内径减小,心室扩张减小,射血分数和室壁缩短率提高(P<0.01)。生化比色法检测血糖及血浆游离脂肪酸结果显示,与对照组相比,糖尿病组血糖及血浆游离脂肪酸水平显著增高,差异有统计学意义(P<0.01);糖尿病+外泌小体组可显著降低血糖及游离脂肪酸水平,差异有统计学意义(P<0.01)。HE染色结果显示,对照组心肌细胞完整,排列整齐;糖尿病组心肌细胞出现肥大、断裂;糖尿病+外泌小体组心肌细胞较完整,排列较整齐。Masson染色结果显示,与对照组相比,糖尿病组纤维化面积显著增大,差异有统计学意义(P<0.01);与糖尿病组比较,糖尿病+外泌小体组纤维化面积减小,差异有统计学意义(P<0.01)。结论:局部注射人脐带间充质干细胞外泌小体可以减轻糖尿病小鼠心肌纤维化,并改善心脏功能。 AIM:To explore the protective effects of exosome secreted by human umbilical mesenchymal stem cells on cardiac fibrosis in diabetic mouse model.METHODS:Male C57BL/6mice at6~8weeks of age were divided into3groups randomly:control group,diabetes mellitus(DM)group and DM+exosome group.To develop mouse DM mo-del,the mice were fed with high-fat diet for5weeks,followed by intraperitoneal injection of45mg/kg streptozocin once a week for5weeks.It was considered as a successful DM model that the blood glucose of the mice was≥16.7mmol/L.The mice in DM+exosome group were injected with exosome via tail vein.The mice in other2groups were injected with saline at the same volume.The heart function was evaluated by color Doppler echocardiography for small animals.The blood samples were collected from abdominal aortas.The blood glucose and non-esterified fatty acids were measured by biochemical colorimetric assay.HE staining was performed to observe the structural changes of myocardial fibers,and Masson staining was used to observe the cardiac fibrosis.RESULTS:The results of echocardiography showed that left ventricular end-diastolic dimension(LVIDd)and left ventricular end-systolic dimension(LVIDs)of diabetic mice were larger than those in control mice(P<0.05and P<0.01,respectively).The ejection fraction(EF)and fractional shortening(FS)decreased in the diabetic mice(P<0.01).Exosome treatment significant decreased the LVIDs(P<0.01),but increased the EF and FS(P<0.01).The blood glucose and non-esterified fatty acids were significantly increased in the diabetic mice.The injection of the stem cell exosome significantly decreased the blood glucose and non-esterified fatty acids(P<0.01).HE staining observation showed that cardiomyocyte hypertrophy and fragmentation of cardiomyocyte in DM group were more se-rious than those in control group.Masson staining showed that the area of fibrosis in DM group was larger than that in control group(P<0.01),but that in DM+exosome group was reduced(P<0.01).CONCLUSION:Exosome secreted by human umbilical mesenchymal stem cells protects the DM model mice from cardiac fibrosis.
作者 黄然然 辛毅 林筝 李娜 HUANG Ranran;XIN Yi;LIN Zheng;LI Na(Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2018年第1期9-14,共6页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81370228) 省部共建重点教育部心血管重塑相关疾病重点实验室项目(No.110267) 北京市卫生系统高层次卫生技术人才培养计划项目(No.2014-3-045)
关键词 人脐带间充质干细胞 外泌小体 糖尿病心肌病 心肌纤维化 Human umbilical mesenchymal stem cells Exosome Diabetic cardiomyopathy Cardiac fibrosis
  • 相关文献

参考文献1

二级参考文献15

  • 1Strauer BE, Steinhoff G. 10 years of intracoronary and in- tramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice [ J ]. J Am Coll Cardiol, 2011, 58 ( 11 ) : 1095-1104.
  • 2Vlassov AV, Magdaleno S, Setterquist R, et al. Exo- somes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials [ J ]. Biochim Biophys Acta, 2012, 1820(7):940-948.
  • 3Frank A, Bonney M, Bonney S, et al. Myocardial ische- mia reperfusion injury: from basic science to clinical bed- side[ J]. Semin Cardiothorac Vasc Anesth,2012, 16(3) : 123-132.
  • 4Wen Z, Zheng S, Zhou C, et al. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarc- tion[J]. J Cell Mol Med, 2011, 15(5) :1032-1043.
  • 5Wen Z, Zheng S, Zhou C, et al. Bone marrow mesenchy- mal stem cells for post-myocardial infarction cardiac re- pair: microRNAs as novel regulators[ J]. J Cell Mol Med, 2012, 16(4) :657-671.
  • 6Tijsen AJ, Pinto YM, Creemers EE. Circulating microR- NAs as diagnostic biomarkers for cardiovascular diseases [J]. Am J Physiol Heart Cire Physiol, 2012, 303(9): H1085-H1095.
  • 7Takaya T, Nishi H, Horie T, et al. Roles of microRNAs and myocardial cell differentiation [ J ]. Prog Mol Biol Transl Sci, 2012, 111:139-152.
  • 8Tang Y, Zheng J, Sun Y, et al. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bel-2 [ J ]. Int Heart J, 2009, 50(3):377-387.
  • 9Jovicic A, Zaldivar Jolissaint JF, Moser R, et al. MicroR- NA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms[ J]. PLoS One, 2013, 8(1) :e54222.
  • 10Huang ZP, Chen J, Seok HY, et al. MicroRNA-22 regu- lates cardiac hypertrophy and remodeling in response to stress [J] Circ Res, 2013, 112(9) : 1234-1243.

共引文献9

同被引文献14

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部